Similarly, in the context of anti‐PD‐1 immunotherapy, MHC‐II+ tumours displayed initial immune activation with CD4+ T cell recruitment but developed adaptive resistance via upregulation of alternative inhibitory receptors such as Lag‐3 and FCRL6.113. Here, CD4 is linked to neoplasm.